Table 2.
Comparisons of comorbidities, anthropometric parameters and cardiovascular risk biomarkers between biochemically controlled (n = 49) and uncontrolled patients (n = 31) and the age- and gender-matched DETECT-controls (n = 196 and n = 120, respectively)
| Patients with uncontrolled acromegaly (n = 31) | Patients with controlled acromegaly (n = 49) | P-value controlled versus uncontrolled acromegaly | DETECT-control group, patients with uncontrolled acromegaly (n = 120) | P-value versus uncontrolled acromegaly | DETECT-control group, patients with controlled acromegaly (n = 196) | P-value versus controlled acromegaly | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | |||||
| Comorbidities | ||||||||||||
| Hypertension | 16 | 51.6 | 27 | 55.1 | 0.762 | 46 | 38.3 | 0.191 | 75 | 38.3 | 0.037 | |
| Diabetes mellitus | 7 | 22.6 | 15 | 30.6 | 0.438 | 23 | 19.2 | 0.676 | 35 | 17.9 | 0.049 | |
| Coronary heart disease | 4 | 12.9 | 3 | 6.1 | 0.309 | 11 | 9.2 | 0.544 | 19 | 9.7 | 0.443 | |
| Myocardial infarction | 0 | 0.0 | 1 | 2.0 | – | 4 | 36.4 | – | 7 | 36.8 | 0.001 | |
| Cerebral insult | 0 | 0.0 | 4 | 8.2 | – | 0 | 0.0 | – | 0 | 0.0 | – | |
| Malignancies | 5 | 16.1 | 4 | 8.2 | 0.283 | 5 | 4.2 | 0.029 | 5 | 2.6 | 0.080 | |
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | ||||
|---|---|---|---|---|---|---|---|
| Anthropometric parameters | |||||||
| Height (cm) | 174.5 (13.5) | 170.7 (10.6) | 0.188 | 170.9 (9.9) | 0.165 | 169.3 (8.7) | 0.391 |
| Weight (kg) | 87.1 (17.2) | 85.6 (17.9) | 0.707 | 81.4 (15.4) | 0.101 | 78.5 (18.5) | 0.015 |
| BMI (kg/m2) | 28.5 (4.0) | 29.5 (5.9) | 0.376 | 27.9 (5.2) | 0.523 | 27.3 (5.8) | 0.020 |
| Waist circumference (cm) | 98.2 (9.8) | 100.9 (16.8) | 0.384 | 97.0 (15.6) | 0.606 | 94.8 (15.5) | 0.031 |
| Hip circumference (cm) | 109.9 (7.4) | 110.7 (9.9) | 0.719 | 106.5 (12.6) | 0.063 | 105.0 (11.7) | 0.001 |
| Waist to height ratio | 0.56 (0.06) | 0.59 (0.10) | 0.190 | 0.57 (0.09) | 0.712 | 0.56 (0.09) | 0.089 |
| Biochemical parameters | |||||||
| IGF-1 (μg/L) | 317.1 (216.7) | 149.1 (47.7) | 0.000 | 135.5 (52.5) | 0.000 | 128.7 (55.5) | 0.011 |
| Cardiovascular risk biomarkers | |||||||
| Fasting plasma glucose (mg/dL) | 97.5 (15.9) | 90.9 (16.7) | 0.084 | 103.7 (27.3) | 0.107 | 104.8 (39.3) | 0.000 |
| HbA1c (%) | 5.8 (0.5) | 5.6 (0.4) | 0.104 | 5.6 (0.9) | 0.069 | 5.7 (1.1) | 0.566 |
| Total cholesterol (mg/dL) | 204.6 (42.1) | 223.6 (36.8) | 0.058 | 225.0 (38.3) | 0.022 | 227.7 (47.6) | 0.534 |
| Triglycerides (mg/dL) | 118.2 (62.3) | 118.5 (59.4) | 0.987 | 174.4 (198.5) | 0.011 | 153.8 (123.1) | 0.006 |
| HDL (mg/dL) | 62.2 (24.8) | 60.0 (19.2) | 0.702 | 51.2 (17.5) | 0.040 | 54.1 (17.6) | 0.077 |
| LDL (mg/dL) | 128.8 (40.1) | 146.9 (34.2) | 0.070 | 129.6 (28.5) | 0.929 | 131.9 (34.8) | 0.013 |
| Lipoprotein (a) (mg/dL) | 40.3 (48.6) | 34.1 (41.7) | 0.706 | 32.3 (43.4) | 0.585 | 34.0 (49.9) | 0.985 |
Note: Significant effects are bold typed